Salutaris Medical Devices, Inc.  announced the first subject was treated in a multi-center clinical trial investigating the use of its ophthalmic brachytherapy device to treat neovascular Age-related Macular Degeneration (nAMD) on May 23, 2018.

SalutarisMD is developing a minimally invasive ophthalmic technology for the treatment of Wet AMD. The technology delivers a single dose of brachytherapy.

TUCSON, AZ. – August 1, 2017 – Salutaris Medical Devices, Inc. today announced the start of a clinical trial investigating the use of its ophthalmic brachytherapy device to treat neovascular Age-related Macular Degeneration (nAMD)

Chandler, Arizona —- As it prepares for its commercial product launch in Europe and new clinical studies in the United States, SalutarisMD® (Salutaris Medical Devices, Inc. and Salutaris Medical Devices, Ltd.) will be in the spotlight at the 2016 AZBio Awards on September 21, 2016 as they are honored with the AZBio Fast Lane Award. […]

HOYA Group has closed financing in Salutaris Medical Devices (SalutarisMD®). SalutarisMD will use the funding to further its growth strategy in developing its patented medical device designed for minimally invasive therapy of wet age-related macular degeneration (wet AMD). Wet AMD is a leading cause of vision loss and blindness that primarily affects older adults.

2017 VENTURE MADNESS COMPETITION – VOTE FOR THE PEOPLE’S CHOICE AWARD by 5:00 PM, on January 24th